Precision treatment for metastatic non-small cell lung cancer: A conceptual overview

Tristan Lee; Jeffrey M Clarke; Deepali Jain; Sendhilnathan Ramalingam; Vishal Vashistha

doi:10.3949/ccjm.88a.19148

Precision treatment for metastatic non-small cell lung cancer: A conceptual overview

Cleve Clin J Med. 2021 Feb 1;88(2):117-127. doi: 10.3949/ccjm.88a.19148.

Authors

Tristan Lee¹, Jeffrey M Clarke², Deepali Jain³, Sendhilnathan Ramalingam², Vishal Vashistha⁴

Affiliations

¹ Columbia University Irving Medical Center, Department of Internal Medicine, New York, NY.
² Duke Cancer Institute, Durham, NC.
³ Department of Pathology, All India Institute of Medical Sciences, Delhi, India.
⁴ Raymond G. Murphy New Mexico Veterans Affairs Medical Center, Section of Hematology/Oncology, Albuquerque, NM vashistha87@gmail.com.

PMID: 33526466
DOI: 10.3949/ccjm.88a.19148

Abstract

Recent developments in precision oncology have increased the complexity of diagnostic and therapeutic decisions. Here, we broadly review the field of precision oncology and discuss common mutational drivers in non-small cell lung cancer (NSCLC) that directly relate to the diagnosis, evaluation, and treatment of patients with metastatic disease.

Publication types

Review

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Mutation
Precision Medicine